IL6 and COVID-19: The diagnosis of NP in severe COVID-19 is difficult, as new infiltrates are poorly visualized in patients with widespread lung damage; leukocytosis can be a demonstration of the known pharmacodynamic effect of systemic GCS, and the use of dexamethasone and interleukine-6 (IL-6) antagonists is associated with a significant decrease in C-reactive protein and procalcitonin and/or the absence of their increase in response to bacterial superinfection [20,21].